Press Releases

 
Press Releases
  Date Title and Summary View
Dec 1, 2016
MONROVIA, Calif., Dec. 1, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 4,585,000 shares of its common stock, offered at a price to the public of $24.00 per share. The gross proceeds from this offering to Xencor are expected to be approximately $110 million, before deducting under...
PDF
Nov 30, 2016
MONROVIA, Calif., Nov. 30, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common sto...
PDF
Nov 13, 2016
MONROVIA, Calif., Nov. 13, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced preliminary data from XmAb5871-03, an ongoing, open-label, pilot Phase 2 study of XmAb5...
PDF
Nov 11, 2016
MONROVIA, Calif., Nov. 11, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that data from preclinical studies on XmAb®20717, a PD-1 x CTLA-4 dual checkpoint ...
PDF
Nov 2, 2016
MONROVIA, Calif., Nov. 2, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today reported financial results for the third quarter ended September 30, 2016 and provided a review of...
PDF
Oct 31, 2016
MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate overview at two upcoming conferences: ...
PDF
Oct 26, 2016
MONROVIA, Calif., Oct. 26, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter 2016 financial results after the market closes on Wednesd...
PDF
Oct 3, 2016
MONROVIA, Calif., Oct. 3, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that preliminary data from an ongoing open-label Phase 2 study of XmAb®5871 in pati...
PDF
Sep 15, 2016
MONROVIA, Calif., Sept. 15, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase 1b multi-dose trial of subcutaneously...
PDF
Sep 12, 2016
MONROVIA, Calif., Sept. 12, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of XmAb®14045 f...
PDF
Page: FirstPrevious
2
... NextLast
Xencor © Copyright 2017